For millennia, aging was considered an immutable law of nature—cells deteriorate, organs fail, and death inevitably follows. Today, we understand that aging is not a predetermined fate but a biological process that can be understood, manipulated, and potentially reversed. The convergence of advanced biotechnology, artificial intelligence, and molecular biology has transformed longevity research from science fiction into a rapidly advancing field with profound implications for human health and society.
Retro Biosciences, raising a staggering $1 billion in funding with initial backing from OpenAI’s Sam Altman, is among the many startups leading this longevity revolution. The company’s first clinical trial, expected to begin at the end of 2025, will test their autophagy-enhancing drug RTR242 – a pill designed to reactivate the body’s cellular “cleanup system” and potentially reverse neurodegenerative damage.
Retro’s goal is not to just add years to life; they want to add life to years. The distinction is crucial because it signals a fundamental shift from managing age-related decline to actively reversing it. The drug RTR242 crosses the blood-brain barrier to enter neurons where it activates cellular processes, targeting the root causes of neurodegeneration rather than just treating symptoms.
The longevity market
The longevity industry was valued at $25 billion in 2020 and is now projected to surpass $600 billion by end of 2025 – a 24-fold increase in just five years. Within the broader longevity ecosystem, the longevity biotech market specifically is expected to rise from $27 billion in 2024 to $46 billion by 2033. This represents not just venture capital speculation but genuine scientific breakthroughs translating into commercial opportunities.
Read more columns from The Review by Ajay Raju
The investment landscape reflects this confidence. Longevity research is now attracting similar levels of capital typically reserved for breakthrough technologies like artificial intelligence or renewable energy. The industry now has several prominent players, including Altos Labs, Calico, Juvenescence, Rubedo Life Sciences. Turn Biotechnologies, BioAge Labs, Cyclarity Therapeutics, Elevian, NewLimit, Shift Bioscience, Insilico Medicine, and Cambrian Bio.
The demographic imperative
The urgency driving these investments becomes clear when examining demographic trends, which represent the most significant population shift since the post-World War II baby boom. The number of people age 65 or older is projected to average 74 million over the next 30 years, about twice the average number of people in that group from the past three decades. This doubling reflects not just the aging of the baby boom generation, but the compounding effect of longer lifespans across all age cohorts.
The financial implications are staggering. Per person personal health care spending for the 65 and older population was $22,356 in 2020, over 5 times higher than spending per child ($4,217) and almost 2.5 times the spending per working-age person ($9,154).
This spending differential translates directly into fiscal pressure. During 2024–33, Medicare spending is projected to grow at a rate of 7.8 percent annually, mostly as a result of strong average enrollment growth. The program’s expanding share of federal resources illustrates the broader fiscal challenge. Half a century ago, Social Security and Medicare spending, combined, accounted for 24 percent of the federal budget. Now, those critical programs account for 36 percent of federal spending. This trend trajectory suggests these programs could consume an unprecedented share of federal resources within the next two decades.
Of course, these projections assume current patterns of aging and age-related disease. If longevity interventions prove successful, they could either dramatically exacerbate these costs (if they extend life without extending healthspan) or revolutionize them entirely (if they extend healthy, productive years).
We have been here before. Previous life extension achievements radically transformed societies. The 20th century saw remarkable gains in human lifespan – from approximately 47 years in 1900 to 76 years by 2000 in developed nations. These gains came primarily from reducing infant mortality, controlling infectious diseases, and improving nutrition and sanitation.
The Review by Ajay Raju: Architects of mass political mobilization (September 22, 2025)
Each wave of previous life extension gains required societal adaptation. The introduction of Social Security in 1935 assumed most people would die before reaching 65. The modern concept of retirement emerged only because improved health allowed people to survive beyond their most productive working years. Universal education systems expanded as childhood became a distinct life phase rather than simply preparation for immediate economic contribution.
Longevity science
Today’s longevity interventions differ fundamentally from historical precedents in that they target the cellular and molecular mechanisms of aging itself. Rather than preventing early death, we now target the biological processes of aging. This means the additional years gained could be healthy, productive years rather than years of managed decline.
The aging process itself is complex, but predictable. The human body operates as a sophisticated biological machine, constantly repairing DNA damage, replacing worn-out proteins, and eliminating dysfunctional cells. Over time, however, these repair mechanisms become less efficient, leading to the accumulation of molecular damage that manifests as wrinkles, cognitive decline, muscle weakness, and increased susceptibility to disease.
This aging process unfolds through several interconnected mechanisms. DNA accumulates mutations and epigenetic changes that alter gene expression patterns. Proteins become damaged by oxidative stress and lose their proper three-dimensional structure, forming toxic aggregates. Mitochondria, the powerhouses of cells, become less efficient at producing energy. Perhaps most significantly, cells themselves become senescent—entering a zombie-like state where they stop dividing but continue to secrete inflammatory molecules that damage surrounding healthy tissue.
These cellular changes don’t occur in isolation. They create a cascade of dysfunction that accelerates with age, explaining why disease risk increases exponentially in later decades of life rather than linearly. The immune system becomes less capable of fighting infections and cancer while simultaneously becoming more prone to attacking healthy tissue. The cardiovascular system stiffens and becomes less efficient. The brain accumulates protein deposits that interfere with normal neural function.
The Review by Ajay Raju: Underperforming American school systems must become AI-powered innovation hubs (October 6, 2025)
Until recently, medical interventions mostly managed the inevitable decline of an aging body. Contemporary science, however, is now capable of slowing down or reversing the progressive breakdown of cellular maintenance systems that normally keep our bodies functioning optimally. These longevity breakthroughs have focused on three primary therapeutic strategies, each targeting different aspects of the aging process with unprecedented precision and promise:
Turning back the clock: the most ambitious approach involves cellular reprogramming —essentially rewinding cells to a younger biological state. This breakthrough emerged from the discovery that specific combinations of transcription factors, known as Yamanaka factors, can convert mature cells back into embryonic-like stem cells. Scientists have learned to partially apply this process, rejuvenating cells without completely erasing their cellular identity.
The integration of artificial intelligence has dramatically accelerated progress in this field. Machine learning algorithms can now predict which combinations of factors will most effectively rejuvenate specific cell types while maintaining their function. Companies leveraging AI-driven approaches report increasing the yield of successfully rejuvenated cells from roughly 1% to significantly higher rates, making therapeutic applications increasingly viable.
This technology holds extraordinary promise for regenerative medicine. Instead of simply treating the symptoms of age-related diseases, cellular reprogramming could restore organs and tissues to a more youthful state. Early experiments have shown remarkable results in animal models, with treated mice displaying improved vision, enhanced cognitive function, and extended lifespans.
Optimizing cellular housekeeping: the second major approach focuses on enhancing autophagy — the cell’s natural recycling system. Like a sophisticated waste management system, autophagy identifies and breaks down damaged cellular components, from misfolded proteins to dysfunctional organelles. This process becomes less efficient with age, leading to the accumulation of cellular debris that contributes to neurodegeneration, muscle weakness, and other age-related pathologies.
The Review by Ajay Raju: Last longer than 30 seconds (
The beauty of autophagy enhancement lies in its potential for broad therapeutic impact. Since autophagy dysfunction contributes to multiple age-related diseases—from Alzheimer’s and Parkinson’s to cardiovascular disease and cancer—interventions that restore this process could simultaneously address numerous aspects of aging. Recent research has identified various pharmacological and lifestyle interventions that can boost autophagy, including specific dietary compounds, intermittent fasting protocols, and targeted medications.
Eliminating cellular zombies: the third pillar involves the targeted elimination of senescent cells—aged cells that have stopped dividing but refuse to die. These cellular zombies secrete inflammatory molecules and growth factors that damage surrounding healthy tissue, contributing to tissue dysfunction and promoting cancer development.
The senolytic drug therapy market represents one of the fastest-growing segments of the longevity industry, with the broader anti-senescence therapy market projected to reach $38.36 billion by 2029. This growth reflects both the therapeutic potential of senescent cell removal and the increasing investment in longevity-focused biotechnology.
Senolytic drugs work by exploiting the vulnerabilities of senescent cells, selectively inducing their death while leaving healthy cells unharmed. Early clinical trials have shown promising results, with participants experiencing improvements in physical function, reduced inflammation markers, and enhanced tissue repair capacity.
Implications for society
If these breakthrough interventions prove successful in extending healthspan by even five to ten years, the ripple effects will reshape virtually every aspect of human civilization.
First, the current healthcare models assume a pattern of gradual decline beginning in the 60s, followed by intensive intervention in the final years of life. If healthspan extends significantly, this model becomes obsolete. Healthcare systems would need to shift from reactive treatment to proactive optimization, focusing on maintaining peak function rather than managing decline.
The economic implications could be staggering. If longevity interventions prevent or delay the onset of Alzheimer’s disease, which currently affects 6.7 million Americans and costs over $320 billion annually, the healthcare savings alone could justify massive public investment in longevity research.
Second, a 100-year lifespan with 80+ years of health fundamentally challenges the traditional three-stage life model of education, career, and retirement. Multiple career phases, sabbatical decades, and continuous education become necessities rather than luxuries.
Consider the financial implications: if someone begins working at 25 and retires at 65, they have 40 years to save for potentially 35+ years of retirement. Extend healthy lifespan by 20 years, and those numbers become untenable without either dramatically increased savings rates or extended working years.
Third, our retirement systems worldwide face existential challenges from current demographic trends. Longevity interventions could either catastrophically accelerate this crisis or provide a solution through extended productive years. The key variable is whether the additional years are healthy and economically productive.
If longevity interventions extend healthspan proportionally with lifespan, the dependency ratio (workers to retirees) could actually improve. If they merely extend years of managed decline, the fiscal burden becomes insurmountable.
The Review by Ajay Raju: The rising tide is lifting mainly yachts(October 20, 2025)
Fourth, consider the insurance and pension systems. Life insurance, health insurance, and disability insurance all operate on actuarial models based on current patterns of aging and death. Successful longevity interventions would require complete recalculation of these models. More fundamentally, they raise questions about fairness and access: if longevity treatments are expensive, do insurance systems subsidize them? What happens to societal cohesion if longevity becomes a luxury good?
Lastly, consider marriages and social relationships. Marriage “until death do us part” takes on new meaning with 100+ year lifespans. Increased lifespans have already contributed to rising divorce rates, as couples face the prospect of 60+ year marriages. Extended lifespans could accelerate this trend or necessitate new models of long-term relationships.
Intergenerational relationships also face disruption. Four or five-generation families become common, with complex inheritance patterns and potentially competing economic interests spanning decades.
Challenges
Despite the optimism and investment, significant challenges remain. First, aging is an extraordinarily complex process involving genetic, environmental, and lifestyle factors. No single intervention is likely to provide dramatic lifespan extension, and the interaction effects between different longevity treatments remain largely unknown.
READ: Buying health insurance after arriving in the US: What Indian visitors should know (
Second, regulatory pathways for longevity interventions are still evolving. The FDA has historically required companies to target specific diseases rather than aging itself. This is beginning to change, but it creates uncertainty about approval timelines and requirements.
Perhaps most importantly, the societal implications of extended lifespans raise ethical questions about equality, resource allocation, and the nature of human experience. If longevity treatments are expensive, they could exacerbate existing inequalities. If they’re widely available, they could strain resources and social systems beyond their capacity.
Assumptions and solutions
If these longevity interventions prove moderately successful, they will extend healthy lifespan by 10-15 years over the next two decades. Society will most likely adapt gradually, with policy changes, work pattern evolution, and infrastructure modifications —all preferably occurring in response to demonstrated results rather than anticipated outcomes.
Healthcare systems will slowly shift toward preventive optimization. Work careers will extend but become more flexible, with multiple career phases and extended sabbaticals. Retirement ages will increase gradually, cushioning the fiscal impact on pension systems.
But if longevity treatments prove successful but remain expensive and exclusive, they will create a bifurcated society where the wealthy live significantly longer than the poor. This poses severe risks to social cohesion and democratic governance. Political systems will struggle with representing populations where voting patterns reflect decades of different life experiences. Economic inequality will become not just about wealth but about fundamental biological advantages. Social tensions will escalate as longevity becomes a marker of class distinction.
In preparation, we must increase investment in longevity research dramatically, both to accelerate breakthroughs and to ensure that successful treatments can be made widely available. Healthcare regulatory systems need updating to accommodate treatments that target aging rather than specific diseases. This includes developing approval pathways for longevity interventions and safety monitoring systems for their long-term effects. Retirement systems, healthcare structures, and educational institutions should build in more flexibility to accommodate varying lifespan scenarios. This includes portable benefits, flexible career structures, and lifelong learning systems. Lastly, society needs robust ethical frameworks for making decisions about longevity treatment access, resource allocation, and the implications of significantly extended lifespans.
Last word
The question is no longer whether longevity interventions will extend human healthspan, but how much, how quickly, and who will benefit. The implications extend far beyond individual health outcomes. We’re potentially facing the most significant transformation in human experience since the agricultural revolution. Like previous transformative changes, success will require not just technological innovation but social, economic, and political adaptation.
The longevity revolution has begun. Are you ready AND prepared for the world it creates?